S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes

Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

$117.28
-2.72 (-2.27%)
(As of 12/8/2023 ET)
Compare
Today's Range
$117.23
$120.32
50-Day Range
$106.07
$120.00
52-Week Range
$89.04
$125.01
Volume
528,392 shs
Average Volume
732,433 shs
Market Capitalization
$11.52 billion
P/E Ratio
63.05
Dividend Yield
N/A
Price Target
$131.71

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
12.3% Upside
$131.71 Price Target
Short Interest
Healthy
2.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.43mentions of Neurocrine Biosciences in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$5.31 M Sold Last Quarter
Proj. Earnings Growth
118.69%
From $2.14 to $4.68 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

80th out of 942 stocks

Biological Products, Except Diagnostic Industry

12th out of 161 stocks


NBIX stock logo

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

NBIX Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Neurocrine Biosciences: Fear Not The IRA
12 Best Low Beta Stocks To Buy
Neurocrine Biosciences Reaches Settlement On INGREZZA ANDA Litigation
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/05/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$131.71
High Stock Price Target
$165.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+12.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

Net Income
$154.50 million
Pretax Margin
14.11%

Debt

Sales & Book Value

Annual Sales
$1.49 billion
Cash Flow
$1.74 per share
Book Value
$17.76 per share

Miscellaneous

Free Float
93,929,000
Market Cap
$11.52 billion
Optionable
Optionable
Beta
0.41
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 65)
    CEO & Director
    Comp: $1.9M
  • Mr. Matthew C. Abernethy (Age 43)
    Chief Financial Officer
    Comp: $1.04M
  • Mr. Darin M. Lippoldt Esq. (Age 57)
    Chief Legal Officer & Corporate Secretary
    Comp: $921.01k
  • Mr. Kyle W. Gano Ph.D. (Age 50)
    Chief Business Development and Strategy Officer
    Comp: $921.52k
  • Dr. Eiry Wyn Roberts M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.04M
  • Dr. Jude Onyia Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $621.66k
  • Jane Sorensen
    Head of Investor Relations
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 57)
    Chief Human Resources Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 58)
    Chief Commercial Officer
    Comp: $805k
  • Mr. David Warren Boyer (Age 44)
    Chief Corporate Affairs Officer














NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price target for 2024?

21 Wall Street research analysts have issued twelve-month target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they anticipate the company's stock price to reach $131.71 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 on January 1st, 2023. Since then, NBIX shares have decreased by 1.8% and is now trading at $117.28.
View the best growth stocks for 2023 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, October, 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.91 by $0.09. The company earned $498.80 million during the quarter, compared to analyst estimates of $479.09 million. Neurocrine Biosciences had a net margin of 10.71% and a trailing twelve-month return on equity of 10.54%. Neurocrine Biosciences's revenue for the quarter was up 28.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.58%), Wellington Management Group LLP (1.35%), DSM Capital Partners LLC (1.25%), Armistice Capital LLC (1.24%), Brown Advisory Inc. (1.12%) and Braidwell LP (0.99%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -